Transmedics Group Inc
NASDAQ:TMDX

  • LAST PRICE
    88.8800
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    88.8400/ 1
  • Ask / Lots
    89.8000/ 1
  • Open / Previous Close
    0.0000 / 88.8800
  • Day Range
    ---
  • 52 Week Range
    36.4201
    99.6300
  • Volume
    201

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Apr 18, 2024

  • Apr 16, 2024

  • Apr 8, 2024

      Show headlines and story abstract

    • 4:05PM ET on Monday Apr 08, 2024 by PR Newswire
      Companies Mentioned: TMDX

      TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on April 4, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 9,722 shares of its common stock and an aggregate of 6,322 restricted stock units to 9 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.

    • 4:05PM ET on Monday Apr 08, 2024 by Dow Jones
      Companies Mentioned: TMDX

      TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      PR Newswire

      ANDOVER, Mass., April 8, 2024

      ANDOVER, Mass., April 8, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on April 4, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 9,722 shares of its common stock and an aggregate of 6,322 restricted stock units to 9 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.

Peers Headlines